SCHEMBL9972908

SCHEMBL9972908

CC(C)c1snc2c1c(=O)n(C)c(=O)n2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
PIK3CD O00329 1/20 0.39
POLB P06746 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
ADORA1 P30542 1/20 0.39
NTSR1 P30989 1/20 0.39
MC3R P41968 1/20 0.39
NOTUM Q6P988 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
GDA Q9Y2T3 1/20 0.39
NR2E1 Q9Y466 1/20 0.39
KDM4E B2RXH2 3/20 0.37
MAPK1 P28482 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716133 0.81 ADORA2B (0.38) KMT2ARXFP1ADORA2AADORA2BPIK3CD
SCHEMBL475287 0.76 ADORA2B (0.37) KMT2AADORA2BPOLBKDM4ELMNA
SCHEMBL9972885 0.72 KDM4E (0.41) KMT2ARXFP1ADORA2AADORA2BKDM4E
SCHEMBL1689509 0.72 KDM4E (0.47) KMT2AADORA2AADORA2BPIK3CDPOLB
SCHEMBL14972716 0.71 KDM4E (0.36) KMT2ARXFP1ADORA2AADORA2BPIK3CD
SCHEMBL9972882 0.69 KMT2A (0.37) KMT2ARXFP1ADORA2AADORA2BPIK3CD
SCHEMBL9972883 0.68 KMT2A (0.46) KMT2ARXFP1ADORA2AADORA2BPIK3CD
SCHEMBL1689535 0.68 ADORA2B (0.40) KMT2ARXFP1ADORA2AADORA2BKDM4E
SCHEMBL13190508 0.67 ALOX15 (0.42) ADORA2BKDM4ELMNAL3MBTL1ALDH1A1
SCHEMBL15472441 0.66 KMT2A (0.37) KMT2ARXFP1POLBKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889862-B2 2-amino-4-arylthiazole compounds as TRPA1 antagonists GLENMARK PHARMACEUTICALS, S.A. (CH) 2014-11-18 US disclosed
US-20140045865-A1 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS GLENMARK PHARMACEUTICALS, S.A. (CH) 2014-02-13 US disclosed
US-20120157411-A1 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157411-A1 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS TRPA1, TRPV1, TRPV2 KMT2A 2406/4885RXFP1 795/4885ADORA2A 81/4885
US-20140045865-A1 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 KMT2A 2625/4885RXFP1 844/4885ADORA2A 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.